Anti-CD19 CAR mRNA-LNP

CD19 is a well-known biomarker expressed on most normal and malignant B cells and used as a target antigen found in B cell malignancies. CD19, also known as B lymphocyte antigen CD19, B lymphocyte surface antigen B4, T cell surface antigen Leu-12, and CVID3, is a transmembrane protein encoded by the gene CD19 in humans. This 95 kd transmembrane glycoprotein belongs to the immunoglobulin superfamily with two extracellular C2 group Ig-like domains and a relatively large cytoplasmic tail that is highly conserved across mammalian species. CD19 is expressed on all normal, mitogen-stimulated, and malignant B cells, with the exception of plasma cells. CD19 is ubiquitously expressed at all stages of B cell development and its surface expression is highly regulated. Because it is ubiquitously present on all B cells, it can serve as a B cell marker and a target for immunotherapy against neoplastic lymphocytes. This product is designed as a tool for the delivery and expression of anti-CD19-41BB-CD3 CAR mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-CD19-41BB-CD3 mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-CD19-41BB-CD3 CAR in this product is approximately 56 kD and consists of anti-CD19 scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. The full-length amino acid sequence of this anti-CD19-41BB-CD3 CAR mRNA-LNP product is available upon request.